Washington, Feb 2 (NationPress) The recent Union Budget has delivered a significant policy message regarding biopharma and healthcare innovation, according to the USA India Chambers of Commerce (USAIC). This includes fresh investments, an expansion of clinical trial infrastructure, and initiatives aimed at achieving global regulatory harmonization.

The government's early commitment to biopharma, exemplified by the Biopharma Shakti initiative and the goal of establishing 1,000 clinical trial sites across the nation, underscores a determined effort to elevate India's position within the global biopharma value chain, remarked USAIC president Karun Rishi in an interview with IANS.

He emphasized that the allocation of ₹10,000 crores to Biopharma Shakti over five years solidifies this commitment. Although modest compared to global standards, Rishi pointed out that this investment sends a robust policy message and fosters the growth of a high-value, high-skill, and technology-driven biopharma ecosystem.

Rishi highlighted that the proposed network of 1,000 clinical trial sites represents a vital step toward enhancing India’s clinical research capabilities.

“For over two decades, USAIC has consistently highlighted the significance of capacity building, skill enhancement, and the expansion of ethical, high-quality clinical trials as essential for India’s rise as a leader in global biopharma innovation,” he stated.

He noted that this announcement reflects a meaningful alignment between longstanding industry engagement and government policy initiatives.

Rishi also praised the government's intention to strengthen and reform the Central Drugs Standard Control Organization to meet global standards and benchmarks.

He asserted that credible regulation, science-based decision-making, and reliable approval timelines are crucial for maintaining global competitiveness in pharmaceuticals.

These priorities were clearly articulated during USAIC’s BioPharma Strategy Session in Delhi last December, which included dialogues with NITI Aayog leadership and senior government officials.

Beyond the pharmaceutical sector, Rishi remarked that Budget 2026 is a confident, forward-looking statement focused on growth, inclusion, and fiscal responsibility amidst increasing global geopolitical and economic uncertainties.

He noted that the government has maintained a course of macroeconomic stability while intensifying efforts in skills, employability, research, science, and innovation.

Rishi emphasized that this signals a clear intent for India's growth narrative to be driven by innovation and future readiness, although successful execution remains the true measure of success.

USAIC commended the Finance Minister and the Government of India for what it termed decisive actions across key sectors.

Noting that the restructuring of the CDSCO is crucial for global regulatory alignment, Rishi suggested that India should consider transitioning from observer to full member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, consistent with India’s scientific capabilities and manufacturing capacity.

He concluded that Budget 2026 signifies a pivotal moment, and effective ongoing implementation could firmly position India on the global biopharma innovation map.